151 related articles for article (PubMed ID: 35660990)
1. Safety and efficacy of melatonin, clonazepam, and trazodone in patients with Parkinson's disease and sleep disorders: a randomized, double-blind trial.
Hadi F; Agah E; Tavanbakhsh S; Mirsepassi Z; Mousavi SV; Talachi N; Tafakhori A; Aghamollaii V
Neurol Sci; 2022 Oct; 43(10):6141-6148. PubMed ID: 35660990
[TBL] [Abstract][Full Text] [Related]
2. [Sleep disorders in Parkinson's disease without dementia: a comparative randomized controlled study of melatonin and clonazepam].
Litvinenko IV; Krasakov IV; Tikhomirova OV
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(12):26-30. PubMed ID: 23388588
[TBL] [Abstract][Full Text] [Related]
3. Prolonged-release melatonin in Parkinson's disease patients with a poor sleep quality: A randomized trial.
Ahn JH; Kim M; Park S; Jang W; Park J; Oh E; Cho JW; Kim JS; Youn J
Parkinsonism Relat Disord; 2020 Jun; 75():50-54. PubMed ID: 32480307
[TBL] [Abstract][Full Text] [Related]
4. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study.
Medeiros CA; Carvalhedo de Bruin PF; Lopes LA; Magalhães MC; de Lourdes Seabra M; de Bruin VM
J Neurol; 2007 Apr; 254(4):459-64. PubMed ID: 17404779
[TBL] [Abstract][Full Text] [Related]
5. Pharmacotherapies for sleep disturbances in dementia.
McCleery J; Sharpley AL
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD009178. PubMed ID: 33189083
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapies for sleep disturbances in Alzheimer's disease.
McCleery J; Cohen DA; Sharpley AL
Cochrane Database Syst Rev; 2014 Mar; (3):CD009178. PubMed ID: 24659320
[TBL] [Abstract][Full Text] [Related]
7. Effects of melatonin prolonged-release on both sleep and motor symptoms in Parkinson's disease: a preliminary evidence.
Liguori C; Fernandes M; Cerroni R; Ludovisi R; Mercuri NB; Stefani A; Pierantozzi M
Neurol Sci; 2022 Sep; 43(9):5355-5362. PubMed ID: 35536495
[TBL] [Abstract][Full Text] [Related]
8. Clonazepam for probable REM sleep behavior disorder in Parkinson's disease: A randomized placebo-controlled trial.
Shin C; Park H; Lee WW; Kim HJ; Kim HJ; Jeon B
J Neurol Sci; 2019 Jun; 401():81-86. PubMed ID: 31035190
[TBL] [Abstract][Full Text] [Related]
9. Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease: A randomised controlled trial.
Gilat M; Coeytaux Jackson A; Marshall NS; Hammond D; Mullins AE; Hall JM; Fang BAM; Yee BJ; Wong KKH; Grunstein RR; Lewis SJG
Mov Disord; 2020 Feb; 35(2):344-349. PubMed ID: 31674060
[TBL] [Abstract][Full Text] [Related]
10. Rasagiline improves polysomnographic sleep parameters in patients with Parkinson's disease: a double-blind, baseline-controlled trial.
Schrempf W; Fauser M; Wienecke M; Brown S; Maaß A; Ossig C; Otto K; Brandt MD; Löhle M; Schwanebeck U; Graehlert X; Reichmann H; Storch A
Eur J Neurol; 2018 Apr; 25(4):672-679. PubMed ID: 29322594
[TBL] [Abstract][Full Text] [Related]
11. Trazodone for sleep disturbance in opioid dependent patients maintained on buprenorphine: A double blind, placebo-controlled trial.
Goyal P; Kattula D; Rao R; Bhad R; Mishra AK; Dhawan A
Drug Alcohol Depend; 2023 Sep; 250():110891. PubMed ID: 37478501
[TBL] [Abstract][Full Text] [Related]
12. Trazodone for sleep disturbance during methadone maintenance: a double-blind, placebo-controlled trial.
Stein MD; Kurth ME; Sharkey KM; Anderson BJ; Corso RP; Millman RP
Drug Alcohol Depend; 2012 Jan; 120(1-3):65-73. PubMed ID: 21798674
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of prolonged-release melatonin versus clonazepam for isolated rapid eye movement sleep behavior disorder.
Byun JI; Shin YY; Seong YA; Yoon SM; Hwang KJ; Jung YJ; Cha KS; Jung KY; Shin WC
Sleep Breath; 2023 Mar; 27(1):309-318. PubMed ID: 35141811
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of melatonin for sleep disturbance in middle-aged primary insomnia: a double-blind, randomised clinical trial.
Xu H; Zhang C; Qian Y; Zou J; Li X; Liu Y; Zhu H; Meng L; Liu S; Zhang W; Yi H; Guan J; Chen Z; Yin S
Sleep Med; 2020 Dec; 76():113-119. PubMed ID: 33157425
[TBL] [Abstract][Full Text] [Related]
15. Serum Levels of Melatonin and Sleep Evaluation Scales in the Diagnosis of Sleep Disorders in Patients with Idiopathic Parkinson's Disease.
Uysal HA; Tıftıkcıoğlu BI; Öcek L; Zorlu Y
Noro Psikiyatr Ars; 2019 Dec; 56(4):264-268. PubMed ID: 31903034
[TBL] [Abstract][Full Text] [Related]
16. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients.
Boeve BF; Silber MH; Ferman TJ
Sleep Med; 2003 Jul; 4(4):281-4. PubMed ID: 14592300
[TBL] [Abstract][Full Text] [Related]
17. Standardized Extract of Valeriana officinalis Improves Overall Sleep Quality in Human Subjects with Sleep Complaints: A Randomized, Double-Blind, Placebo-Controlled, Clinical Study.
Chandra Shekhar H; Joshua L; Thomas JV
Adv Ther; 2024 Jan; 41(1):246-261. PubMed ID: 37899385
[TBL] [Abstract][Full Text] [Related]
18. Sodium Oxybate for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson Disease: A Randomized Clinical Trial.
Büchele F; Hackius M; Schreglmann SR; Omlor W; Werth E; Maric A; Imbach LL; Hägele-Link S; Waldvogel D; Baumann CR
JAMA Neurol; 2018 Jan; 75(1):114-118. PubMed ID: 29114733
[TBL] [Abstract][Full Text] [Related]
19. Safinamide improves sleep and daytime sleepiness in Parkinson's disease: results from the SAFINONMOTOR study.
Santos García D; Cabo López I; Labandeira Guerra C; Yáñez Baña R; Cimas Hernando MI; Paz González JM; Alonso Losada MG; Gonzalez Palmás MJ; Cores Bartolomé C; Martínez Miró C
Neurol Sci; 2022 Apr; 43(4):2537-2544. PubMed ID: 34554335
[TBL] [Abstract][Full Text] [Related]
20. Study of Exogenous Melatonin as a Treatment Modality for Sleep and Psychiatric Disorders in Hemodialysis Patients.
Yousef EA; El Wasify MA; Baddor AA; Sobh MA
Saudi J Kidney Dis Transpl; 2022; 33(1):1-15. PubMed ID: 36647974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
